Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme/Isis’ Mipomersen Development Outlook Pricier And Riskier After FDA Weighs In

This article was originally published in The Pink Sheet Daily

Executive Summary

Cardiotoxicity and outcomes requirements push back NDA timeline for the novel LDL-lowering drug.

You may also be interested in...



Top Ten Unpartnered Drugs: It's Tough To Make The Grade In CVD/Metabolics

Early-stage talent parade will be held at Windhover's Therapeutic Area Partnerships conference next week.

Top Ten Unpartnered Drugs: It's Tough To Make The Grade In CVD/Metabolics

Early-stage talent parade will be held at Windhover's Therapeutic Area Partnerships conference next week.

GSK Goes To The Heart Of The Problem With Outcomes Study For Darapladib

GlaxoSmithKline is applying a lesson the pharmaceutical industry learned from recent events in cardiovascular drug development: do an outcomes study, and start it early

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067662

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel